Search the Newsreel

The Oncology Institute Changes Name to Starling Oncology

The Oncology Institute, Inc. has officially changed its name to Starling Oncology, Inc. The company, which manages community-based oncology practices across 86 clinic locations in five states, continues to provide medical oncology services, including physician services, infusion, radiation, and clinical trials. This name change …

Wells Fargo initiates Pyxis Oncology stock with overweight rating By Investing.com

Wells Fargo has initiated coverage on Pyxis Oncology Inc. (NASDAQ:PYXS) with an overweight rating and a price target of $12.00, citing the potential of its MICVO treatment for head and neck squamous cell carcinoma. Despite a recent nine percent decline, the stock has seen …

Colony Bankcorp, Inc. Revenue Breakdown – NYSE:CBAN

Colony Bankcorp, Inc. (NYSE:CBAN) generated $132.18 million in revenue last year, with its Bank segment being the top performer, contributing $112.60 million. The company's revenue primarily comes from the United States, which accounted for the entire $132.18 million in the previous year. This indicates …

Wells Fargo Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $12

Wells Fargo has initiated coverage on Pyxis Oncology (PYXS.US) with a Buy rating. The firm has set a target price of $12 for the company's stock. This initiation suggests a positive outlook from Wells Fargo regarding Pyxis Oncology's future performance.

The Oncology Institute Rebrands as Starling Oncology

The Oncology Institute (TOI), a major value-based oncology group in the U.S., has officially rebranded as Starling Oncology, Inc. The company's stock will now trade on Nasdaq under the new ticker symbol "STLN" starting August 4, 2026. This rebrand signifies the company's growth and …

Edward Canup Buys 2,000 Shares of Colony Bankcorp (NYSE:CBAN) Stock

Aktis Oncology (AKTS) Expected to Release Earnings on Monday

Price to sales forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

This article provides financial information for The Oncology Institute, Inc. (NASDAQ:TOIIW) focusing on its price to sales forward metric. It appears to be a financial data page from TradingView, displaying market data, financial figures, and general company information for the stock.

Enterprise value to EBITDA forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

The article provides financial information for The Oncology Institute, Inc. (NASDAQ: TOIIW), focusing on its enterprise value to EBITDA forward. It is presented within the TradingView platform, detailing financial metrics and market data related to the company.

Price to earnings forward of The Oncology Institute, Inc. – NASDAQ:TOIIW

The article presents financial information for The Oncology Institute, Inc. (NASDAQ: TOIIW), specifically focusing on its price-to-earnings forward metric. It appears to be a stub or a section of a larger financial data platform, providing a snapshot of the company's financial overview without detailed …

Enterprise value to EBITDA forward of Champions Oncology, Inc. – NASDAQ:CSBR

The article focuses on the "Enterprise value to EBITDA forward" financial metric for Champions Oncology, Inc. (NASDAQ: CSBR). It appears to be a financial data snippet or a specific metric page from TradingView, providing financial information for the company. The content lists various sections …

Kura Oncology, Inc. $KURA Shares Sold by Renaissance Technologies LLC

Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen

Champions Oncology, Inc. Revenue Breakdown – NASDAQ:CSBR

Champions Oncology, Inc. (NASDAQ: CSBR) generated $59.42 million in revenue last year, primarily from its Pharmacology Services segment, which contributed $57.13 million. The majority of this revenue, $59.42 million, came from operations within the United States. This represents an increase from the previous year's …

BlackRock, Inc. Reduces Colony Bankcorp Inc (CBAN) Stake -- Shar

BlackRock, Inc. has reduced its stake in Colony Bankcorp Inc (CBAN) by selling 558,665 shares at $20.09 each, a transaction that had a 0% impact on BlackRock's overall portfolio. This move comes as CBAN's stock has seen significant appreciation and is considered modestly overvalued …

Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis

Kura Oncology Inc (KURA) has a current financial score of 6.02, indicating a weak financial status and low operating efficiency within the Biotechnology & Medical Research industry. Despite this, the company reported a year-over-year revenue increase of 29.47% and a net profit increase of …

BlackRock, Inc. Slashes Cardiff Oncology (CRDF) Stake by 78.3%

BlackRock, Inc. significantly reduced its stake in Cardiff Oncology Inc. (CRDF) by 78.32%, selling over 3.1 million shares. This move reflects BlackRock's shift away from speculative biotech ventures towards more established technology and financial services companies. Cardiff Oncology faces significant financial challenges, including unprofitability …

Should You Buy Colony Bankcorp, Inc. (NYSE:CBAN) For Its Upcoming Dividend?

Colony Bankcorp, Inc. (NYSE:CBAN) is scheduled to go ex-dividend in four days, with a payment of US$0.12 per share, representing a 2.2% trailing yield. The company's dividend appears sustainable with a modest payout ratio of 28% of profit and earnings per share growing at …

Vanguard Capital Management (CBAN) discloses 4.92% Colony Bankcorp ownership in 13G amendment

Vanguard Capital Management LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 4.92% in Colony Bankcorp Inc (CBAN), totaling 1,042,729 shares as of June 30, 2026. The filing indicates that Vanguard has sole voting power over 136,381 shares and sole dispositive …

CG Oncology (CGON) to Post Earnings on Friday

CTOR|Citius Oncology Inc|Price:0.654|Chg%:+0.062

Does Asahi Songwon Colors (NSE:ASAHISONG) Deserve A Spot On Your Watchlist?

Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Kura Oncology Inc (KURA), highlighting its current earnings forecast score, analyst ratings, and price targets. The company ranks 146 out of 384 in the Biotechnology & Medical Research industry, with most analysts recommending a "Buy" for the …

Form 4 Oncology Institute Inc For: 29 July By Investing.com

This article announces the filing of Form 4 for Oncology Institute Inc. on July 29. It appears to be a standard financial news brief from Investing.com, providing basic information about the regulatory filing. The content itself is minimal, serving primarily as a notification rather …

Oncology Institute (TOI) grants 29,116 RSUs to company director

Oncology Institute (TOI) director Kimberly Jo Tzoumakas was granted 29,116 restricted stock units (RSUs) on July 27, 2026. These RSUs, which vest fully at the company's 2027 annual meeting of stockholders, increase her direct holdings to 46,301 shares. The grant is a form of …

Oncology Institute, Inc. (TOI) awards 33,133 RSUs to director Kaushal Mohit

Oncology Institute, Inc. (TOI) director Kaushal Mohit was granted 33,133 restricted stock units (RSUs) on July 27, 2026, as reported in a Form 4 filing. These RSUs will vest in full at the company’s 2027 annual meeting of stockholders, provided Mohit continues his service. …

Champions Oncology Q4 Earnings Call Highlights

Champions Oncology (CSBR) reported record revenue of $59.4 million for fiscal 2026, driven by its Translational Oncology Solutions business, and achieved positive adjusted EBITDA in all four quarters. The company saw services revenue increase by 12% to $58.7 million, with improved gross margins due …

CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push

Champions Oncology (CSBR) shares dipped by 10.9% following its Q4 earnings report, despite record revenue growth in fiscal 2026 driven by its core research services. The company experienced an operating loss for the full year but saw narrowed diluted losses per share and improved …

Is Champions Oncology (NASDAQ:CSBR) In A Good Position To Invest In Growth?

Champions Oncology (NASDAQ:CSBR) has a cash runway of approximately 12 months based on its current cash burn of US$5.0m and cash reserves of US$4.9m as of April 2026. While this short runway is a concern, its revenue grew by 4.4% last year, and its …

Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk

Cardiff Oncology Inc (CRDF) currently has a risk assessment score of 3.90, ranking 107 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of 1.35 indicates higher volatility compared to the S&P 500. The article details various risk metrics …

TOI|Oncology Institute Inc|Price:4.755|Chg%:-0.195

This article provides a comprehensive stock analysis of Oncology Institute Inc (TOI), highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Providers & Services industry. It notes a high institutional ownership and a positive outlook from analysts, with a highest …

The Oncology Institute, Inc. Revenue Breakdown – NASDAQ:TOIIW

The Oncology Institute, Inc. (NASDAQ: TOIIW) generated $502.73 million USD in revenue last year. Its top-performing segment was Dispensary, contributing $269.18 million USD, a significant increase from $179.92 million USD the previous year. The United States was the primary geographic contributor, accounting for all …

Kura Oncology (KURA) to Announce Quarterly Earnings on Thursday

Oncology Institute (TOI) to Release Quarterly Earnings on Thursday

Cullinan Therapeutics (CGEM) Expected to Release Quarterly Earnings on Thursday

Champions Oncology Inc (CSBR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Champions Oncology Inc (CSBR), noting its current valuation score of 8.90 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -31.65, which is significantly below its recent high and above its …